Browsing Tag

RZ358

Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with…

Jason Junior Jun 28, 2023

Study to be initiated in Europe and other ex-US geographies in Q4 2023, with topline results expected 1H 2025 Conference call scheduled today at 4:30 p.m. ET REDWOOD CITY, Calif., June 27, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. …

Health

Rezolute Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital…

Jason Junior May 1, 2022

Highly significant ~75% reduction in hypoglycemia events at anticipated therapeutic doses≥50% improvement in hypoglycemia in 100% of patients in high-dose cohort, with no adverse drug reactions or clinically significant hyperglycemiaStudy…

Health

RZ358 Phase 2b (RIZE Study) Topline Data to be Unveiled at Pediatric Endocrine Society Annual…

Jason Junior Apr 27, 2022

Rezolute to host conference call presentation and discussion of the data on Sunday, May 1 at 2:30 p.m. ET REDWOOD CITY, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company…

Health

Rezolute Announces Initiation of Dosing in the Second Cohort of its Phase 2b Trial of RZ358 for…

Jason Junior Sep 10, 2021

Tracking to Announce Top line data in Q1 2022 REDWOOD CITY, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases…